利奈唑胺与万古霉素治疗耐甲氧西林金黄色葡萄球菌感染疗效及安全性荟萃分析  

Meta-analysis of efficacy and safety of linezolid and vancomycin in treatment of methicillin-resistant Staphylococcus aureus infection

作　　者：柯邵鹏[1,2] 刘江福[2] 苏智军[2] 郭如意[2] 陈素梅[2] 林琪[2] 

机构地区：[1]泉州医学高等专科学校,福建泉州362000 [2]福建医科大学附属泉州第一医院感染科,福建泉州362000

出　　处：《中华医院感染学杂志》2015年第6期1281-1284,共4页Chinese Journal of Nosocomiology

基　　金：福建省医学创新基金资助项目(2012-CX-33)

摘　　要：目的系统评价利奈唑胺和万古霉素治疗耐甲氧西林金黄色葡萄球菌(MRSA)感染的临床疗效及安全性。方法计算机检索Cochrane图书馆、PubMed、Embase、CNKI全文数据库、维普中文科技期刊数据库中2013年6月前发表关于利奈唑胺和万古霉素治疗MRSA感染的随机对照试验文献,并应用STATA软件进行统计分析。结果共纳入11篇文献,合计5 567例患者,MRSA所致肺炎者利奈唑胺组临床治愈率、细菌清除率均高于万古霉素组(P<0.05);MRSA所致复杂性皮肤软组织感染(cSTTI)者采用利奈唑胺治疗临床治愈率、细菌清除率均高于万古霉素组(P<0.05);利奈唑胺的肾功能不全、不良反应发生率均低于万古霉素(P<0.05),消化系统不良反应高于万古霉素(P<0.01)。结论对于MRSA所致的肺炎、cSTTI感染,利奈唑胺的临床及微生物疗效优于万古霉素。OBJECTIVE To systematically evaluate the clinical efficacy and safety of linezolid and vancomycin in treatment of methicillin-resistant Staphylococcus aureus （MRSA ） infection .METHODS The Cochrane Library , PubMed ,Embase ,CNKI full-text database ,and VIP Chinese scientific journals database were retrieved to collect the literatures regarding the randomized controlled trials for linezolid and vancomycin in treatment of MRSA infec -tion that were published before Jun 2013 ,and the statistical analysis was performed with the use of stata software . RESULTS Totally 11 literatures were included ,with 5 567 patients involved .The clinical cure rate of the patients with MRSA pneumonia was higher in the linezolid group than in the vancomycin group ;the bacterial clearance rate of the linezolid group was higher than that of the vancomycin group （P〈 0 .05） .The clinical cure rate of the pa-tients with MRSA complicated skin and soft tissue infection （cSSTI） was higher in the linezolid group than in the vancomycin group ;the bacterial clearance rate of the linezolid group was higher than that of the vancomycin group （P〈 0 .05） .The incidence of renal dysfunction or adverse reactions was lower in the linezolid group than in the vancomycin group （P〈 0 .05） ;while the incidence of gastrointestinal adverse reactions was higher in the linezolid group than in the vancomycin group （P〈 0 .01） .CONCLUSION Linezolid is superior to vancomycin in the clinical , microbial efficacy in the treatment of pneumonia or cSSTI caused by MRSA .

关 键 词：利奈唑胺 万古霉素 耐甲氧西林金黄色葡萄球菌 荟萃分析 

分 类 号：R978.1[医药卫生—药品]